Rigel Pharmaceuticals to Showcase Innovations at Jefferies Global Healthcare Conference in London

Rigel Pharmaceuticals to Present at the Jefferies Global Healthcare Conference

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a cutting-edge biotechnology firm headquartered in South San Francisco, California, is poised to make a significant impact during the upcoming Jefferies Global Healthcare Conference taking place in London. Scheduled for Tuesday, November 18, 2025, at 10:00 AM GMT (5:00 AM ET), the company’s president and CEO, Raul Rodriguez, will present an overview of Rigel's initiatives and advancements in the field of hematologic disorders and cancer.

Event Details

The Jefferies Global Healthcare Conference is a prominent forum that showcases innovations and breakthroughs in the healthcare sector. This year’s event will host a variety of industry leaders, and Rigel’s participation highlights the company's commitment to improving patient outcomes through novel therapies. Attendees can access the live webcast of Rigel’s presentation and view an archived recording by navigating to the investor relations section of the company’s official website, www.rigel.com. It is advisable for viewers to connect to Rigel's website before the live event to ensure smooth access and any necessary software downloads.

About Rigel Pharmaceuticals

Founded in 1996, Rigel Pharmaceuticals has established itself as a leader in biopharmaceutical development, focusing on the discovery and delivery of therapies for patients suffering from hematologic disorders and cancer. With a robust pipeline and several marketed products, Rigel is dedicated to enhancing patient lives through innovative treatment options. The organization’s primary mission revolves around harnessing advanced scientific research and technology to create therapies that address critical unmet medical needs.

In a landscape where advancements in biotechnology are transforming treatment pathways, Rigel stands out with its strategic focus on hematological malignancies and other significant health challenges. The company's efforts have led to notable advances in understanding the biological mechanisms behind various cancers, contributing to the field of oncology.

Key Areas of Focus

Rigel is committed to fostering innovation in the realm of hematologic disorders and cancers. The company works tirelessly on developing therapies that can potentially shift the treatment paradigm for these serious conditions. With ongoing clinical trials and research, Rigel aims to provide hope and improved health outcomes for affected patients.

Investor Engagement

For investors and stakeholders interested in the latest updates, Rigel’s presentations at major conferences like Jefferies not only provide insights into the company’s operational strategies and pipeline developments but also emphasize its commitment to transparency and engagement within the investment community. Rigel's media and investor relations team remains accessible for inquiries, helping to build a bridge of communication and understanding about the company's mission and future goals.

As Rigel Pharmaceuticals prepares for its presentation at the Jefferies conference, anticipation grows around its potential disclosures regarding innovative therapies and strategic developments that could shape the future of treatment options for hematologic disorders and cancer. The company is dedicated to progressing science in the fight against cancer and providing meaningful advancements that could change the lives of patients worldwide. For more information about Rigel, its product pipeline, and efforts in research and development, visit their official website.

To connect with Rigel for additional inquiries, investment interests or media engagements, please contact:

- Investors: Rigel Pharmaceuticals, Inc. at 650.624.1232 or via email at [email protected]
- Media: David Rosen at Argot Partners, reachable at 646.461.6387 or via email at [email protected].